Archive for the 'Lung Cancer' Category
New Model May Simplify High-Dose Radiosurgery Planning
There is yet no straightforward way to determine the optimal dose level and treatment schedules for high-dose radiation therapies such as stereotactic radiation therapy, which is used to treat brain and lung cancer, or for high-dose brachytherapy for prostate and other cancers. Radiation oncologists at the Ohio State University Comprehensive Cancer Center-Arthur G…Original post by The Health Wisdom Blog™ (by OrganizedWisdom)
No commentsValue Of Oxygen Therapy In End-Of-Life Care Challenged By Study
Millions of patients with advanced disease in palliative care settings receive oxygen therapy to help them breathe more easily. But a new study from Duke University Medical Center says roughly half of them don’t benefit from the intervention, and among those who do benefit, it doesn’t make a bit of difference whether they get pure oxygen or just plain old room air - both offer equal benefit…Original post by Lemonade Life
No commentsIn Lung Cancer, Tumor Budding Identified As Predictor For Unfavorable Outcome
Lung cancer is the leading cause of cancer deaths worldwide, and the prognosis is generally poor, even if surgery is successful. Furthermore, the incidence of one type of lung cancer, adenocarcinoma, has been increasing in recent years…Original post by Lemonade Life
No commentsUse Of In Vitro Drug Response Assay Shows Promise In Lung Cancer Treatment
Chemotherapy is the best broad defense against cancer recurrence after surgical resection. However, it is difficult to predict which patients will benefit from which regimen of anticancer drugs, if at all…Original post by Lemonade Life
No commentsAmerican Lung Association Supports Individuals Dealing With Lung Disease Through Online Caregiving Coordination Service
The American Lung Association is offering a free-of-charge, online caregiving coordination service called “My Fighting for Air Community” to support individuals affected by acute and chronic lung diseases…Original post by Lemonade Life
No commentsMetformin May Protect Against Lung Cancer
Metformin, a drug commonly used to treat type 2 diabetes, shows potential in the prevention of tobacco-induced lung tumors, according to early research conducted at the National Cancer Institute (NCI). Results of this study will be published in the September issue of Cancer Prevention Research, a journal of the American Association for Cancer Research. Scott Lippman, M.D…Original post by Lemonade Life
No commentsDecreasing Lung Cancer Risk By Eating A Diverse Diet Of Vegetables
Adding a variety of vegetables to one’s diet may help decrease the chance of getting lung cancer, and adding a variety of fruits and vegetables may decrease the risk of squamous cell lung cancer, especially among smokers. Study results are published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research…Original post by Pharmalot
No commentsPlant Agents Show Promise In Preventing Skin Cancer
Maybe you worshipped the sun in your youth or weren’t as meticulous as you should have been with sunscreen. If so, take heart: Scientists at The University of Texas Health Science Center San Antonio are finding that certain plant substances, when given in combinations, may suppress damage that can cause skin cancer…Original post by Pharmalot
No commentsTopline Results From Phase 3 Trial Of Sunitinib With Erlotinib In Advanced Non-Small Cell Lung Cancer (NSCLC)
Pfizer Inc. (NYSE 
FE) announced that the SUN 1087 trial of sunitinib in combination with erlotinib versus erlotinib demonstrated a statistically significant improvement in Progression-Free but not in Overall Survival in patients with previously treated advanced non-small cell lung cancer (NSCLC)…Original post by Consumer Reports Health Blog
Arqule And Daiichi Sankyo Move Forward With Phase 3 Clinical Trial Plan For Arq 197 In Non-Small Cell Lung Cancer
ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo Co., Ltd. (TSE 4568) announced that they will move forward with a Phase 3 clinical trial of ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase, in patients with non-small cell lung cancer (NSCLC). In connection with this decision, the sponsor company, Daiichi Sankyo, will file a Special Protocol Assessment (SPA) with the U.S…Original post by Consumer Reports Health Blog
No comments